Opiant Pharmaceuticals Inc. [OPNT] Chief Executive Officer makes an insider purchase of 1,358 shares worth 27513.0.


Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Opiant Pharmaceuticals Inc. shares valued at $27,513 were sold by CRYSTAL ROGER on Jan 27. At $20.26 per share, CRYSTAL ROGER sold 1,358 shares. The insider’s holdings dropped to 75,339 shares worth approximately $1.56 million following the completion of this transaction.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Also, Ellison Mark Jason Heath sold 610 shares, netting a total of over 12,359 in proceeds. Following the sale of shares at $20.26 each, the insider now holds 18,751 shares.

Before that, O’Toole David D had sold 541 shares from its account. In a trade valued at $10,961, the Chief Financial Officer traded Opiant Pharmaceuticals Inc. shares for $20.26 each. Upon closing the transaction, the insider’s holdings decreased to 541 shares, worth approximately $0.71 million.

As published in their initiating research note from Oppenheimer on December 09, 2021, Opiant Pharmaceuticals Inc. [OPNT] has been an Outperform and the price target has been revised to $42. This represents a 50.83% premium over Wednesday’s closing price. Analysts at Northland Capital started covering the stock with ‘”an Outperform”‘ outlook in a report released in late May.

Analyzing OPNT Stock Performance

On Wednesday, Opiant Pharmaceuticals Inc. [NASDAQ: OPNT] plunged -0.58% to $20.65. The stock’s lowest price that day was $20.50, but it reached a high of $21.00 in the same session. During the last five days, there has been a drop of approximately -1.05%. Over the course of the year, Opiant Pharmaceuticals Inc. shares have jumped approximately 1.82%. Shares of the company reached a 52-week high of $21.46 on 02/16/23 and a 52-week low of $19.96 on 01/26/23. A 50-day SMA is recorded $20.48, while a 200-day SMA reached $14.66. Nevertheless, trading volume fell to 0.56 million shares from 36100.0 shares the previous day.

Support And Resistance Levels for Opiant Pharmaceuticals Inc. (OPNT)

According to the 24-hour chart, there is a support level at 20.43, which, if violated, would cause prices to drop to 20.22. In the upper region, resistance lies at 20.93. The next price resistance is at 21.22. RSI (Relative Strength Index) is 50.13 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.15, which suggests the price will decrease in the coming days. Percent R is at 84.38%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Opiant Pharmaceuticals Inc. subject to short interest?

Stocks of Opiant Pharmaceuticals Inc. saw a sharp steep in short interest on Jan 12, 2023 dropping by 2840.0 shares to 27810.0. Data from Yahoo Finance shows that the short interest on Dec 14, 2022 was 30650.0 shares. A decline of -10.21% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.43 of the overall float, the days-to-cover ratio (short ratio) decline to 0.43.

Which companies own the most shares of Opiant Pharmaceuticals Inc. (OPNT)?

According to Western Standard LLC filings, the company currently owns 424,080 shares, which is about 8.21% of the total OPNT shares outstanding. With the completion of the buy transaction, Apis Capital Advisors LLC’s stake is now worth $4,318,520. Morgan Stanley & Co. LLC acquire a 28,266.81% interest valued at $3.93 million while The Vanguard Group, Inc. purchased a 3,615 stake. A total of -30,500 shares of Opiant Pharmaceuticals Inc. were bought by Renaissance Technologies LLC during the quarter, and -68,303 were sold by Wells Fargo Clearing Services LLC. In its current portfolio, Dimensional Fund Advisors LP holds 100,209 shares valued at $2.02 million.

In terms of Opiant Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $21.50 in the next 12 months, up nearly 3.51% from the previous closing price of $20.77. Analysts anticipate Opiant Pharmaceuticals Inc. stock to reach $22.00 by 2023, with the lowest price target being $21.00. In spite of this, 2 analysts ranked Opiant Pharmaceuticals Inc. stock as a Hold at the end of 2023.


Please enter your comment!
Please enter your name here